{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:14:25Z","timestamp":1764785665296,"version":"3.45.0"},"reference-count":136,"publisher":"Tech Science Press","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.066708","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T08:34:17Z","timestamp":1753086857000},"page":"2181-2204","source":"Crossref","is-referenced-by-count":1,"title":["Combining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives"],"prefix":"10.32604","volume":"33","author":[{"given":"Raffaele","family":"Carrano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlotta","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicla","family":"Cristina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora Leti","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Bei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Infante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Focaccetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Lucarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Cifaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Masuelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Benvenuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.21037\/jtd-20-2761","article-title":"Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature","volume":"13","author":"Schumann","year":"2021","journal-title":"J Thorac Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/1878-0261.13591","article-title":"Pleural mesothelioma (PMe): the evolving molecular knowledge of a rare and aggressive cancer","volume":"18","author":"Rigon","year":"2024","journal-title":"Mol Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.3390\/cancers16233956","article-title":"Mesothelioma of the Tunica vaginalis testis: diagnostic and therapeutic management, a comprehensive review, 1982\u20132024","volume":"16","author":"Stella","year":"2024","journal-title":"Cancers"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1002\/cam4.5915","article-title":"Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: a review of the National Cancer Database","volume":"12","author":"Bou-Samra","year":"2023","journal-title":"Cancer Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"200226","DOI":"10.1183\/16000617.0226-2020","article-title":"Update on biology and management of mesothelioma","volume":"30","author":"Asciak","year":"2021","journal-title":"Eur Respir Rev"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3390\/cells12162048","article-title":"Chronic inflammation, oxidative stress and metabolic plasticity: three players driving the pro-tumorigenic microenvironment in malignant mesothelioma","volume":"12","author":"Fiorilla","year":"2023","journal-title":"Cells"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00428-021-03031-7","article-title":"Pleural mesothelioma classification update","volume":"478","author":"Beasley","year":"2021","journal-title":"Virchows Arch"},{"key":"ref8","first-page":"e20210129","article-title":"Malignant pleural mesothelioma: an update","volume":"47","author":"Hajj","year":"2021","journal-title":"J Bras Pneumol"},{"key":"ref9","first-page":"1","article-title":"An update on emerging therapeutic options for malignant pleural mesothelioma","volume":"13","author":"Davis","year":"2022","journal-title":"Lung Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/cancers17060979","article-title":"An overview of cellular and molecular determinants regulating chemoresistance in pleural mesothelioma","volume":"17","author":"Cortes-Dericks","year":"2025","journal-title":"Cancers"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e65903","DOI":"10.1371\/journal.pone.0065903","article-title":"Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy","volume":"8","author":"Szulkin","year":"2013","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10555-007-9049-z","article-title":"Molecular basis of antifolate resistance","volume":"26","author":"Assaraf","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2018.03.022","article-title":"Loss of C\/EBP-\u03b2 LIP drives cisplatin resistance in malignant pleural mesothelioma","volume":"120","author":"Kopecka","year":"2018","journal-title":"Lung Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.21.01567","article-title":"New era for malignant pleural mesothelioma: updates on therapeutic options","volume":"40","author":"Tsao","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jtho.2024.01.017","article-title":"Immunotherapy is a good standard option for patients with malignant pleural mesothelioma, despite the real-world results from Australia","volume":"19","author":"Smesseim","year":"2024","journal-title":"J Thorac Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2024.01.016","article-title":"Based on the real-world results from Australia, immunotherapy is not a good option for patients with mesothelioma","volume":"19","author":"Gray","year":"2024","journal-title":"J Thorac Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e221490","DOI":"10.1001\/jamanetworkopen.2022.1490","article-title":"Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma","volume":"5","author":"Meirson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0960327114542965","article-title":"EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells","volume":"34","author":"Onen","year":"2015","journal-title":"Hum Exp Toxicol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"76577","DOI":"10.18632\/oncotarget.10428","article-title":"Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines","volume":"7","author":"Monica","year":"2016","journal-title":"Oncotarget"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"216395","DOI":"10.1016\/j.canlet.2023.216395","volume":"574","author":"Schelch","year":"2023","journal-title":"Cancer Lett"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/1471-2407-13-400","article-title":"Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts","volume":"13","author":"Macura","year":"2013","journal-title":"BMC Cancer"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2020.05.023","article-title":"Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells","volume":"146","author":"Otsuka","year":"2020","journal-title":"Lung Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e057663","DOI":"10.1136\/bmjopen-2021-057663","article-title":"Protocol of DREAM3R: durvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial","volume":"12","author":"Kok","year":"2022","journal-title":"BMJ Open"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jtho.2017.05.021","article-title":"Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"12","author":"Tsao","year":"2017","journal-title":"J Thorac Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-Na\u00efve patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"37","author":"Tsao","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.annonc.2024.12.014","article-title":"A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamaoncol.2023.6789","article-title":"Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma","volume":"10","author":"Szlosarek","year":"2024","journal-title":"JAMA Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/mt.2010.159","article-title":"Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms","volume":"18","author":"Fridlender","year":"2010","journal-title":"Mol Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN\u03b1 combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/ijc.30228","article-title":"Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5\/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model","volume":"139","author":"Kuryk","year":"2016","journal-title":"Int J Cancer"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e007552","DOI":"10.1136\/jitc-2023-007552","article-title":"ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment","volume":"11","author":"Ponce","year":"2023","journal-title":"J Immunother Cancer"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e1457597","DOI":"10.1080\/2162402X.2018.1457597","article-title":"A single centre phase II trial to assess the immunological activity of TroVax\u00ae plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma\u2014the SKOPOS trial","volume":"7","author":"Lester","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","volume":"25","author":"Hassan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e0307204","DOI":"10.1371\/journal.pone.0307204","article-title":"Integration of the PD-L1 inhibitor atezolizumab and WT1\/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study","volume":"19","author":"Van den Bossche","year":"2024","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e026779","DOI":"10.1136\/bmjopen-2018-026779","article-title":"Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial","volume":"9","author":"de Boer","year":"2019","journal-title":"BMJ Open"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e007070","DOI":"10.1136\/jitc-2023-007070","article-title":"Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial","volume":"11","author":"Dietz","year":"2023","journal-title":"J Immunother Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1259314","DOI":"10.3389\/fonc.2023.1259314","article-title":"Novel combinatorial therapy of oncolytic adenovirus AdV5\/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model","volume":"13","author":"Garofalo","year":"2023","journal-title":"Front Oncol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/toxins10110470","article-title":"SS1P immunotoxin induces markers of immunogenic cell death and enhances the effect of the CTLA-4 blockade in AE17M mouse mesothelioma tumors","volume":"10","author":"Leshem","year":"2018","journal-title":"Toxins"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/2326-6066.CIR-17-0530","article-title":"AMD3100 augments the efficacy of mesothelin-targeted, immune-activating VIC-008 in mesothelioma by modulating intratumoral immunosuppression","volume":"6","author":"Li","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"ref46","first-page":"100756","article-title":"Combining a WT1 vaccine (galinpepimut-S) with checkpoint inhibition (nivolumab) in patients with WT1-expressing diffuse pleural mesothelioma: a phase 1 study","volume":"6","author":"Agrawal","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12967-021-02905-3","article-title":"NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma","volume":"19","author":"Haakensen","year":"2021","journal-title":"J Transl Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1080\/09637486.2023.2251723","article-title":"Curcumin potentiates the ErbB receptors inhibitor Afatinib for enhanced antitumor activity in malignant mesothelioma","volume":"74","author":"Benvenuto","year":"2023","journal-title":"Int J Food Sci Nutr"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.fct.2012.10.060","article-title":"Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells","volume":"52","author":"Lee","year":"2013","journal-title":"Food Chem Toxicol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.fct.2016.08.033","article-title":"Cisplatin and resveratrol induce apoptosis and autophagy following oxidative stress in malignant mesothelioma cells","volume":"97","author":"Lee","year":"2016","journal-title":"Food Chem Toxicol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12906-016-1267-x","article-title":"Quercetin and Cisplatin combined treatment altered cell cycle and mitogen activated protein kinase expressions in malignant mesotelioma cells","volume":"16","author":"Demiroglu-Zergeroglu","year":"2016","journal-title":"BMC Complement Altern Med"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"851589","DOI":"10.1155\/2010\/851589","volume":"2010","author":"Demiroglu-Zergeroglu","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.taap.2013.10.025","article-title":"Combination of ascorbate\/epigallocatechin-3-gallate\/gemcitabine synergistically induces cell cycle deregulation and apoptosis in mesothelioma cells","volume":"274","author":"Martinotti","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp Mol Med"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/antib14020035","article-title":"A comprehensive review about the use of monoclonal antibodies in cancer therapy","volume":"14","author":"Justiz-Vaillant","year":"2025","journal-title":"Antibodies"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the biological missile for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent advances and limitations of mTOR inhibitors in the treatment of cancer","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","article-title":"Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)","volume":"77","author":"Cedr\u00e9s","year":"2012","journal-title":"Lung Cancer"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.3390\/molecules27196229","article-title":"Folic acid antimetabolites (antifolates): a brief review on synthetic strategies and application opportunities","volume":"27","author":"Kovalev","year":"2022","journal-title":"Molecules"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"117369","DOI":"10.1016\/j.ejmech.2025.117369","article-title":"Advancing Src kinase inhibition: from structural design to therapeutic innovation\u2014a comprehensive review","volume":"287","author":"Su","year":"2025","journal-title":"Eur J Med Chem"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"105695","DOI":"10.1016\/j.phrs.2021.105695","article-title":"Histone deacetylase 2 selective inhibitors: a versatile therapeutic strategy as next generation drug target in cancer therapy","volume":"170","author":"Shetty","year":"2021","journal-title":"Pharmacol Res"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"340","DOI":"10.14740\/wjon1655","article-title":"Biology of mesothelin and clinical implications: a review of existing literature","volume":"14","author":"Hagerty","year":"2023","journal-title":"World J Oncol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"23136","DOI":"10.1038\/s41598-024-72118-3","article-title":"Preclinical comparison of prolgolimab, pembrolizumab and nivolumab","volume":"14","author":"Gordeev","year":"2024","journal-title":"Sci Rep"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J Thorac Oncol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S1470-2045(21)00640-9","article-title":"RAMES study: is there really a role for VEGF inhibition in mesothelioma?","volume":"22","author":"Porta","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2217\/fon-2017-0307","article-title":"A review of bevacizumab in the treatment of malignant pleural mesothelioma","volume":"13","author":"Brosseau","year":"2017","journal-title":"Future Oncol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: eSMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cac2.12183","article-title":"Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges","volume":"41","author":"Li","year":"2021","journal-title":"Cancer Commun"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1470-2045(23)00446-1","article-title":"Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study","volume":"24","author":"Douma","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1165\/rcmb.2011-0195OC","article-title":"Nutritional stress and arginine auxotrophy confer high sensitivity to chloroquine toxicity in mesothelioma cells","volume":"46","author":"Battisti","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.3390\/cancers14246063","article-title":"Immune checkpoint inhibitors in malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"14","author":"Gemelli","year":"2022","journal-title":"Cancers"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"104372","DOI":"10.1016\/j.critrevonc.2024.104372","article-title":"Evaluation of first-line and salvage therapies for unresectable malignant mesothelioma: a systematic review and network meta-analysis","volume":"198","author":"Zhuang","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"101324","DOI":"10.1016\/j.mam.2024.101324","article-title":"Cancer vaccines: target antigens, vaccine platforms and preclinical models","volume":"101","author":"Ruzzi","year":"2025","journal-title":"Mol Aspects Med"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/genes15070903","article-title":"A comprehensive review of HER2 in cancer biology and therapeutics","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.3390\/ijms22126567","article-title":"MUC1: structure, function, and clinic application in epithelial cancers","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12935-024-03624-7","article-title":"Telomerase-based vaccines: a promising frontier in cancer immunotherapy","volume":"24","author":"Vahidi","year":"2024","journal-title":"Cancer Cell Int"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"77872","DOI":"10.18632\/oncotarget.20845","article-title":"Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1","volume":"8","author":"Eguchi","year":"2017","journal-title":"Oncotarget"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/17476348.2019.1563488","article-title":"Immunotherapy strategies for mesothelioma\u2014the role of tumor specific neoantigens in a new era of precision medicine","volume":"13","author":"Ye","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","article-title":"Application of immunohistochemistry in diagnosis and management of malignant mesothelioma","volume":"9","author":"Chapel","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jtho.2018.06.008","article-title":"Trophoblast glycoprotein is associated with a favorable outcome for mesothelioma and a target for antibody drug conjugates","volume":"13","author":"Schunselaar","year":"2018","journal-title":"J Thorac Oncol"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.lungcan.2012.03.008","article-title":"Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma","volume":"77","author":"Al-Taei","year":"2012","journal-title":"Lung Cancer"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"1684713","DOI":"10.1080\/2162402X.2019.1684713","volume":"9","author":"Sneddon","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex chromosomal rearrangements in mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J Thorac Oncol"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3390\/ph16101384","article-title":"Tumor vaccines: unleashing the power of the immune system to fight cancer","volume":"16","author":"Liu","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.21037\/tlcr-20-673","article-title":"Immunotherapy in malignant pleural mesothelioma: a review of literature data","volume":"10","author":"Menis","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3390\/ijms23041975","article-title":"Novel and future treatment options in mesothelioma: a systematic review","volume":"23","author":"\u0160trbac","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.3390\/cancers15245787","article-title":"Current state-of-the-art therapy for malignant pleural mesothelioma and future options centered on immunotherapy","volume":"15","author":"Cedres","year":"2023","journal-title":"Cancers"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/17460441.2020.1811673","article-title":"Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer","volume":"16","author":"Kerr","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3390\/vaccines11121783","article-title":"Cancer vaccines in the immunotherapy era: promise and potential","volume":"11","author":"Verma","year":"2023","journal-title":"Vaccines"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/2326-6066.CIR-24-0245","article-title":"Hyperthermic intrathoracic chemotherapy modulates the immune microenvironment of pleural mesothelioma and improves the impact of dual immune checkpoint inhibition","volume":"13","author":"Hao","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/1471-2407-10-464","article-title":"COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function","volume":"10","author":"Veltman","year":"2010","journal-title":"BMC Cancer"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jconrel.2023.01.034","article-title":"Liposomal celecoxib combined with dendritic cell therapy enhances antitumor efficacy in melanoma","volume":"354","author":"Jahani","year":"2023","journal-title":"J Control Release"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors\u2014an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J Immunother Cancer"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/cancers17030503","article-title":"A meta-analysis of first-line treatments for unresectable pleural mesothelioma: indirect comparisons from reconstructed individual patient data of six randomized controlled trials","volume":"17","author":"Messori","year":"2025","journal-title":"Cancers"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/imt.12.108","article-title":"Dendritic cell-based immunotherapy in mesothelioma","volume":"4","author":"Cornelissen","year":"2012","journal-title":"Immunotherapy"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3390\/cancers17040694","article-title":"Recent advances in mesothelioma treatment: immunotherapy, advanced cell therapy, and other innovative therapeutic modalities","volume":"17","author":"Suraya","year":"2025","journal-title":"Cancers"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(24)00191-8","article-title":"Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2\/3 study","volume":"25","author":"Aerts","year":"2024","journal-title":"Lancet Oncol"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cytogfr.2023.11.002","article-title":"Harnessing the potential of CD40 agonism in cancer therapy","volume":"75","author":"Zhou","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3390\/biom10070973","article-title":"Mesothelin-targeted recombinant immunotoxins for solid tumors","volume":"10","author":"Hagerty","year":"2020","journal-title":"Biomolecules"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-8722-7-15","article-title":"A novel mycobacterial Hsp70-containing fusi on protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma","volume":"7","author":"Yuan","year":"2014","journal-title":"J Hematol Oncol"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.semcancer.2021.12.011","article-title":"Multifaceted role of chemokines in solid tumors: from biology to therapy","volume":"86","author":"Raza","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.2174\/0109298673284605240301035057","article-title":"Adjuvant anti-tumor therapy with polyphenolic compounds: a review","volume":"32","author":"Gareev","year":"2025","journal-title":"Curr Med Chem"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3390\/ijms20071714","article-title":"Polyphenols as immunomodulatory compounds in the tumor microenvironment: friends or foes?","volume":"20","author":"Focaccetti","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/ph14111068","article-title":"New insights into curcumin- and resveratrol-mediated anti-cancer effects","volume":"14","author":"Arena","year":"2021","journal-title":"Pharmaceuticals"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/nu8050275","article-title":"The potential protective effects of polyphenols in asbestos-mediated inflammation and carcinogenesis of mesothelium","volume":"8","author":"Benvenuto","year":"2016","journal-title":"Nutrients"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"107700","DOI":"10.1016\/j.pharmthera.2020.107700","article-title":"Targeting the tumor immune microenvironment with nutraceuticals: from bench to clinical trials","volume":"219","author":"Masuelli","year":"2021","journal-title":"Pharmacol Ther"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/biomedicines12030482","article-title":"Dietary polyphenols effects on focal adhesion plaques and metalloproteinases in cancer invasiveness","volume":"12","author":"Carrano","year":"2024","journal-title":"Biomedicines"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.3390\/ijms21186635","volume":"21","author":"Benvenuto","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"12023","DOI":"10.3390\/ijms140612023","volume":"14","author":"Zhou","year":"2013","journal-title":"Int J Mol Sci"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ijc.23328","volume":"122","author":"Somers-Edgar","year":"2008","journal-title":"Int J Cancer"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"35242","DOI":"10.1039\/C4RA06616B","article-title":"Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells","volume":"4","author":"Wang","year":"2014","journal-title":"RSC Adv"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"34405","DOI":"10.18632\/oncotarget.14907","article-title":"Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line","volume":"8","author":"Masuelli","year":"2017","journal-title":"Oncotarget"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fphar.2017.00373","volume":"8","author":"Masuelli","year":"2017","journal-title":"Front Pharmacol"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3389\/fphar.2018.01269","volume":"9","author":"Benvenuto","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.3390\/cancers15205003","article-title":"Evening primrose extract modulates TYMS expression via SP1 transcription factor in malignant pleural mesothelioma","volume":"15","author":"Chmielewska-Kassassir","year":"2023","journal-title":"Cancers"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3390\/biom10111574","volume":"10","author":"Chmielewska-Kassassir","year":"2020","journal-title":"Biomolecules"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"C183","DOI":"10.1152\/ajpcell.00428.2024","article-title":"Natural compounds and strategies for fighting against drug resistance in cancer: a special focus on phenolic compounds and microRNAs","volume":"329","author":"Petrovi\u0107","year":"2025","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"12587","DOI":"10.3390\/ijms241612587","article-title":"An overview of the enhanced effects of curcumin and chemotherapeutic agents in combined cancer treatments","volume":"24","author":"Cacciola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.3390\/ijms16059236","volume":"16","author":"Fantini","year":"2015","journal-title":"Int J Mol Sci"},{"key":"ref129","first-page":"2531","article-title":"Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma","volume":"53","author":"Zhang","year":"2018","journal-title":"Int J Oncol"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.21037\/tlcr-21-201","article-title":"Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study","volume":"10","author":"Mathilakathu","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2012.07.005","article-title":"Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy","volume":"78","author":"Fischer","year":"2012","journal-title":"Lung Cancer"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jn\/nxz029","article-title":"Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial","volume":"149","author":"Howells","year":"2019","journal-title":"J Nutr"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/nu13010273","article-title":"Polyphenols and human health: the role of bioavailability","volume":"13","author":"Di Lorenzo","year":"2021","journal-title":"Nutrients"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2021.05.001","article-title":"Resveratrol for cancer therapy: challenges and future perspectives","volume":"515","author":"Ren","year":"2021","journal-title":"Cancer Lett"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"113956","DOI":"10.1016\/j.biopha.2022.113956","article-title":"Curcumin: an epigenetic regulator and its application in cancer","volume":"156","author":"Ming","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"13","DOI":"10.18231\/j.ctppc.2022.004","article-title":"Polyphenols: the interactions with CYP isoenzymes and effect on pharmacokinetics of drugs","volume":"4","author":"Bhamre Vaibhav","year":"2022","journal-title":"Curr Trends Pharm Pharm Chem"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-9\/OncolRes-33-09-66708\/OncolRes-33-66708.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:13:54Z","timestamp":1763345634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n9\/63639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":136,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.066708","relation":{},"ISSN":["1555-3906"],"issn-type":[{"type":"electronic","value":"1555-3906"}],"subject":[],"published":{"date-parts":[[2025]]}}}